CGT Catapult Partners with MICA Biosystems

Independent innovation and technology organization, the Cell and Gene Therapy Catapult (CGT Catapult), has partnered with medical technology company, MICA Biosystems, with the aim of advancing MICA’s regenerative medicine technology to the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

MICA has developed a remote-controlled stem cell platform for regenerative medicine that employs nanotechnology. The initial use of the platform is for spinal fusion, but in the future the company wants to apply the technology to the field of regenerative medicine. According to a Feb. 10, 2022 press release, the collaboration between MICA and CGT Catapult is important to aid with the conversations with MHRA, with whom alignment is key to ensure smooth clinical trial transitions.

“This collaboration will provide a boost to ensure MICA is able to begin clinical trials in a timely manner and, most importantly, allow our technology to reach patients sooner,” said Michal Zurawski, CEO at MICA Biosystems, in the press release. “This new chapter in our development was made possible by an injection of investment from the UK Government and Innovate UK, recognising MICA as a real innovator and disruptor in the space of regenerative medicine. With the expertise and experience of the CGT Catapult, we aim to launch our medicines as an accessible treatment option for millions of patients with a number of life-changing diseases and injuries which currently have limited or no treatment options.”

“Our vision for the CGT Catapult is to help develop a thriving industry delivering life changing advanced therapies to the world,” added Matthew Durdy, CEO at Cell and Gene Therapy Catapult, in the press release. “We are looking forward to working with MICA as an innovative company and welcome the support from the Innovate UK EDGE fund that will enable this collaboration to leverage our unique expertise to help bring MICA’s innovative technology solutions to patients.”

Source: CGT Catapult